Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AADI Aadi Bioscience	$1.90 +1.6%	$1.76	$1.21 ▼ $3.81	$46.92M	0.68	266,476 shs	82,732 shs
ABP Abpro	$0.21 -5.4%	$0.23	$0.15 ▼ $13.00	$13.56M	-0.03	5.52 million shs	2.64 million shs
ADVM Adverum Biotechnologies	$2.32 -6.8%	$2.60	$1.78 ▼ $10.14	$52.02M	0.71	279,794 shs	2.80 million shs
GANX Gain Therapeutics	$1.97 -1.0%	$1.88	$0.89 ▼ $3.19	$59.59M	0.11	296,541 shs	282,966 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AADI Aadi Bioscience	+0.53%	-7.32%	+5.56%	-0.52%	+18.75%
ABP Abpro	-5.38%	+1.10%	-17.74%	-49.76%	+21,099,900.00%
ADVM Adverum Biotechnologies	-6.83%	+3.11%	+4.98%	-49.67%	-66.76%
GANX Gain Therapeutics	-1.01%	+11.30%	+9.44%	+4.23%	+55.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AADI Aadi Bioscience	0.5888 of 5 stars	1.0	0.0	0.0	0.0	1.1	2.5	1.3
ABP Abpro	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ADVM Adverum Biotechnologies	4.2903 of 5 stars	3.4	3.0	0.0	4.8	1.7	2.5	0.6
GANX Gain Therapeutics	3.2963 of 5 stars	3.6	5.0	0.0	0.0	3.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AADI Aadi Bioscience	2.00	Hold	$1.67	-12.28% Downside
ABP Abpro	3.00	Buy	$4.00	1,795.73% Upside
ADVM Adverum Biotechnologies	2.80	Moderate Buy	$23.80	925.86% Upside
GANX Gain Therapeutics	3.17	Buy	$8.20	316.24% Upside

Current Analyst Ratings Breakdown

Latest ABP, GANX, ADVM, and AADI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $12.00
5/19/2025	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/15/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00
5/15/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
5/15/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/17/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $33.00
4/16/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$10.00 ➝ $5.00
4/16/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/28/2025	GANX Gain Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AADI Aadi Bioscience	$25.07M	1.87	N/A	N/A	$4.29 per share	0.44
ABP Abpro	$180K	71.26	N/A	N/A	($0.29) per share	-0.73
ADVM Adverum Biotechnologies	$1M	48.46	N/A	N/A	$3.40 per share	0.68
GANX Gain Therapeutics	$50K	1,180.03	N/A	N/A	$0.28 per share	7.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AADI Aadi Bioscience	-$65.76M	-$2.35	N/A	N/A	N/A	-246.06%	-71.87%	-57.28%	8/5/2025 (Estimated)
ABP Abpro	-$7.23M	N/A	0.00	∞	N/A	N/A	N/A	-198.95%	N/A
ADVM Adverum Biotechnologies	-$130.93M	-$6.40	N/A	N/A	N/A	N/A	-130.53%	-66.31%	8/11/2025 (Estimated)
GANX Gain Therapeutics	-$20.41M	-$0.86	N/A	N/A	N/A	N/A	-247.55%	-146.06%	8/6/2025 (Estimated)

Latest ABP, GANX, ADVM, and AADI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	N/A	ABP Abpro	N/A	-$0.08	N/A	-$0.08	N/A	N/A
5/14/2025	Q1 2025	GANX Gain Therapeutics	-$0.16	-$0.16	N/A	-$0.16	$0.03 million	N/A
4/15/2025	Q4 2024	ADVM Adverum Biotechnologies	-$1.34	-$1.96	-$0.62	-$1.96	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AADI Aadi Bioscience	N/A	N/A	N/A	N/A	N/A
ABP Abpro	N/A	N/A	N/A	N/A	N/A
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AADI Aadi Bioscience	N/A	4.89	4.54
ABP Abpro	N/A	0.11	0.11
ADVM Adverum Biotechnologies	N/A	3.57	3.57
GANX Gain Therapeutics	0.05	2.22	2.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AADI Aadi Bioscience	52.08%
ABP Abpro	23.30%
ADVM Adverum Biotechnologies	48.17%
GANX Gain Therapeutics	11.97%

Insider Ownership

Company	Insider Ownership
AADI Aadi Bioscience	37.30%
ABP Abpro	20.80%
ADVM Adverum Biotechnologies	6.00%
GANX Gain Therapeutics	7.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AADI Aadi Bioscience	40	24.70 million	15.49 million	Optionable
ABP Abpro	15	60.79 million	48.14 million	N/A
ADVM Adverum Biotechnologies	190	20.89 million	19.64 million	Optionable
GANX Gain Therapeutics	20	29.95 million	27.80 million	Optionable

ABP, GANX, ADVM, and AADI Headlines

Recent News About These Companies

Scotiabank Sticks to Its Buy Rating for Gain Therapeutics (GANX)

June 27 at 5:58 PM | theglobeandmail.com

Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.20 Consensus PT from Analysts

June 18, 2025 | americanbankingnews.com

Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of "Buy" by Analysts

June 15, 2025 | marketbeat.com

Gain Therapeutics to Participate in Upcoming Investor Conferences

June 10, 2025 | globenewswire.com

Gain Therapeutics, Inc. Announces Oral Presentation at GBA1 Meeting 2025 in Montreal

May 29, 2025 | quiverquant.comQ

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

May 29, 2025 | globenewswire.com

Gain Therapeutics (GANX) Gets a Buy from Scotiabank

May 16, 2025 | theglobeandmail.com

Gain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

May 14, 2025 | finanznachrichten.de

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

May 14, 2025 | globenewswire.com

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

May 13, 2025 | finance.yahoo.com

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

May 12, 2025 | globenewswire.com

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

May 1, 2025 | globenewswire.com

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

April 30, 2025 | finance.yahoo.com

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

April 30, 2025 | globenewswire.com

Gain Therapeutics presents additional data on study of GT-02287

April 11, 2025 | markets.businessinsider.com

Is Gain Therapeutics (GANX) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?

April 11, 2025 | insidermonkey.com

Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update

April 10, 2025 | manilatimes.netM

Gain Therapeutics (GANX) Receives a Buy from Roth MKM

March 31, 2025 | markets.businessinsider.com

Gain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

March 28, 2025 | finanznachrichten.de

Scotiabank Keeps Their Buy Rating on Gain Therapeutics (GANX)

March 28, 2025 | markets.businessinsider.com

Gain Therapeutics Announces Poster Presentation at AD/PD 2025

March 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP, GANX, ADVM, and AADI Company Descriptions

Aadi Bioscience NASDAQ:AADI

$1.90 +0.03 (+1.60%)

As of 06/26/2025

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Abpro NASDAQ:ABP

$0.21 -0.01 (-5.38%)

As of 06/27/2025 04:00 PM Eastern

Abpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.

Adverum Biotechnologies NASDAQ:ADVM

$2.32 -0.17 (-6.83%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.30 -0.02 (-0.86%)

As of 06/27/2025 07:22 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Gain Therapeutics NASDAQ:GANX

$1.97 -0.02 (-1.01%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.96 0.00 (-0.25%)

As of 06/27/2025 07:32 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time